CAR-T infusion

BIOLOGICAL3 trials

Sponsors

The First Affiliated Hospital of Soochow University, The Third Affiliated Hospital of Guangzhou Medical University, Shambavi Richard

Conditions

Acute Leukemia in RemissionMultiple MyelomaPlatelet Transfusion RefractorinessRefractory Metastatic Colorectal CancerRelapsed/Refractory Multiple Myeloma

Early Phase 1

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

The Third Affiliated Hospital of Guangzhou Medical UniversityRefractory Metastatic Colorectal Cancer

Start: 2021-09-13End: 2022-10-31Target: 9Updated: 2022-02-21

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Not yet recruitingNCT07727668

Shambavi RichardMultiple Myeloma, Relapsed/Refractory Multiple Myeloma

Start: 2026-07-01End: 2031-07-01Target: 22Updated: 2026-07-27

Phase 1

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

The First Affiliated Hospital of Soochow UniversityAcute Leukemia in Remission, Platelet Transfusion Refractoriness

Start: 2021-04-29End: 2024-03-31Target: 20Updated: 2021-10-27

Related Papers

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Blood2024-11-051 citations